Aug. 31, 2009 (Business Wire) -- Geron Corporation (Nasdaq:GERN) today announced that the company will present updates of its product development programs at four investor conferences in the month of September.
Stephen M. Kelsey, M.D., F.R.C.P., F.R.C.Path., executive vice president and chief medical officer for oncology, will review Geron’s portfolio of anti-cancer therapies, including its telomerase inhibitor drug (imetelstat - GRN163L) and its telomerase therapeutic vaccine (GRNVAC1) at the following conference:
- Rodman & Renshaw 11th Annual Healthcare Conference in New York, NY, at 9:35 am ET on Thursday, September 10, 2009.
Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company’s anti-cancer therapies and the company’s human embryonic stem cell (hESC) development programs for spinal cord injury (GRNOPC1), heart disease (GRNCM1) and diabetes (GRNIC1) at the following conferences:
- Thomas Weisel Partners Healthcare Conference in Boston, MA, at 9:45 am ET on Friday, September 11, 2009.
- G6: ThinkEquity’s 6th Annual Growth Conference in San Francisco, CA, at 2:45 pm PT on Wednesday, September 16, 2009.
- UBS Global Life Sciences Conference in New York, NY, at 3:30 pm ET on Tuesday, September 22, 2009. The webcast link for the live audio and slide presentation at this conference will be available on the Events page of Geron’s website at: www.geron.com. The presentation will be archived for replay after the conference for a period of 30 days.
About Geron
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials in different cancers. For more information, visit www.geron.com.
